Lilly reports detailed Phase III data for Cyramza in first-line gastric cancer

Eli Lilly and Co. (NYSE:LLY) reported additional data from the Phase III RAINFALL trial in 645 patients with HER2-negative metastatic gastric or gastroesophageal junction adenocarcinoma showing that IV Cyramza ramucirumab (IMC-1121B,

Read the full 311 word article

User Sign In